Production (Stage)
Celldex Therapeutics, Inc.
CLDX
$20.34
-$0.92-4.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -53.80M | -47.09M | -42.12M | -35.84M | -32.81M |
| Total Depreciation and Amortization | 867.00K | 819.00K | 786.00K | 797.00K | 775.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.05M | 6.42M | 5.29M | 2.90M | 3.90M |
| Change in Net Operating Assets | -8.50M | 7.38M | -19.29M | 2.82M | -12.50M |
| Cash from Operations | -54.37M | -32.48M | -55.34M | -29.33M | -40.64M |
| Capital Expenditure | -265.00K | -756.00K | -545.00K | -274.00K | -344.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 43.22M | 24.80M | 48.30M | -46.45M | -314.87M |
| Cash from Investing | 42.95M | 24.05M | 47.76M | -46.72M | -315.21M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 202.00K | 386.00K | 1.24M | 3.71M | 436.11M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 202.00K | 386.00K | 1.24M | 3.71M | 436.11M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -11.22M | -8.04M | -6.34M | -72.34M | 80.26M |